Inclusion Criteria:

- Patients with a histological diagnosis of a primary CNS tumor (including
histologically benign brain tumors (e.g. low-grade glioma) that is recurrent,
progressive, or refractory to standard therapy; patients with intrinsic brain stem or
diffuse optic pathway tumors do not require histological confirmation of disease but
should have clinical and/or radiographic evidence of progression

- Karnofsky Performance Scale (KPS for >= 16 yrs of age) or Lansky Performance Score
(LPS for ≤ 16 years of age) ≥ 60 assessed within two weeks prior to registration

- Patient must be able to swallow capsules

- Patients must have recovered from any significant acute toxicity associated with
prior therapy; patients must have no known curative therapy available; patients will
be eligible regardless of the number of prior therapies, as long as other eligibility
criteria are met

- Chemo: Prior use of thalidomide is acceptable; patients must have:

- Received their last dose of known myelosuppressive anticancer chemotherapy or
biological therapy at least three (3) weeks prior to study registration

- Received their last dose of nitrosourea or mitomycin-C at least six (6) weeks
prior to study registration

- Received their last dose of other investigational agent or an anticancer drug
known to not be myelosuppressive at least seven (7) days prior to study
registration

- XRT: Patients must have had their last fraction of craniospinal irradiation ≥ 3
months prior to registration and their last fraction of local irradiation to primary
tumor ≥ 4 weeks prior to registration

- Bone Marrow Transplant: ≥ 6 months since allogeneic bone marrow transplant and ≥ 3
months since autologous bone marrow/stem cell prior to registration

- Growth factors: Off all colony forming growth factor(s) > 2 weeks prior to
registration (filgrastim, sargramostim, erythropoietin)

- The following laboratory values must be assessed within two (2) weeks prior to
registration and again within seven (7) days prior to the start of therapy;
laboratory tests should be repeated within 48 hours of beginning therapy if there has
been a significant clinical change

- Absolute neutrophil count ≥ 1000/μl (unsupported)

- Platelets ≥ 100,000/μl (unsupported)

- Hemoglobin ≥ 8.0 g/dL (may be supported)

- Serum creatinine within upper limit of institutional normal for age

- Or GFR ≥ 70 ml/min/1.73m^2

- Bilirubin ≤ 1.5 times upper limit of normal for age

- SGPT (ALT) ≤ 2.5x institutional upper limit of normal for age

- Albumin ≥ 2 g/dL

- No overt renal, hepatic, cardiac or pulmonary disease

- Female patients of childbearing potential must have negative serum or urine pregnancy
test (sensitivity of at least 50mIU/ml); patients must not be pregnant or
breast-feeding

- All sexually active females must begin 2 methods of birth control, including 1 highly
effective method, and 1 additional method (at the same time) at least 4 weeks prior
to the first dose of CC-5013; this applies to all sexually active females of
childbearing potential unless they have not had a menstrual period in 2 years or have
undergone a hysterectomy

- Patients of child fathering potential must agree to use latex condoms during
intercourse with a woman while taking CC-5013 and for 4 weeks thereafter

- Signed informed consent according to institutional guidelines must be obtained

Exclusion Criteria:

- Patients with a body surface area (BSA) ≤ 0.4 m^2 are excluded

- Patients with a first-degree relative with a history of venous thrombosis before age
50 yrs or an arterial thrombosis before age 40 yrs are excluded

- Patients who have had a thromboembolic event that is not line-related are excluded

- Patients with any significant medical illnesses that, in the investigator's opinion,
cannot be adequately controlled with appropriate therapy or would compromise a
patient's ability to tolerate this therapy

- Patients with any disease that would obscure toxicity or dangerously alter drug
metabolism

- Patients receiving any other chemotherapeutics or investigational agents

- Patients with uncontrolled infection

- Patients unable to swallow capsules

- Patients with known hypersensitivity to anhydrous lactose, microcrystalline
cellulose, croscarmellose sodium, and magnesium stearate